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Abstract
Background: Seizures are a common presenting sign in dogs with brain tumors.
Hypothesis/Objectives: To investigate the effect of radiotherapy on freedom from
brain tumor-associated seizures and survival time in dogs.
Animals: Thirty-two client-owned dogs with brain tumor-associated seizures;
18 received medical treatment and radiotherapy, 14 received medical treatment alone.
Methods: Multicenter retrospective study. Baseline characteristics (seizure semiol-
ogy, magnetic resonance imaging [MRI] characteristics, and treatment) and duration
of seizure freedom were recorded for the 2 treatment groups. Duration of seizure
freedom between groups was compared (log-rank test) using Cox's proportional haz-
ard analysis, with baseline characteristics entered as covariates.
Results: The duration of seizure freedom and survival time were significantly longer
in the radiotherapy group (P < .001), with a mean of 24 months (95% confidence
interval [CI], 14.3-33.8) versus 1.7 months in the control group (95% CI, 0.5-2.9) and
a mean of 34.6 months (95% CI: 25.2-44.1) versus 6.2 months in the control group
(95% CI, 2.6-9.7) respectively. Baseline characteristics were not associated with dura-
tion of seizure freedom after the start of treatment. In the radiotherapy group, 5 dogs
were euthanized during the study period because of causes other than seizures. In
the control group, recurrence of seizures was observed before death in all dogs.
Conclusions and Clinical Importance: A longer period of seizure freedom and longer
survival time was observed in dogs with brain tumors after radiotherapy compared to
medical treatment only. The pathophysiological mechanisms of epileptogenesis and
the effect of radiation therapy on seizure control are unclear to date. Further pro-
spective studies are needed.
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1 | INTRODUCTION
Seizures are a common presenting clinical manifestation in dogs with
brain tumors1 and are a major concern of the owners of affected dogs
because they are perceived to greatly affect the animal's quality of life.
In veterinary medicine, control of seizure activity in patients with
brain tumors is mainly based on the use of antiepileptic drugs (AED)
and steroidal anti-inflammatory drugs. Other treatment modalities
reported in conjunction with medical treatment include surgical resec-
tion, chemotherapy or radiotherapy.2,3
In human patients, there has been interest in investigating the
role of surgical resection, chemotherapy and radiotherapy in seizure
control.4,5 Radiation therapy improves seizure control in humans, but
no similar studies are available in dogs.5
Our aim was to investigate the effect of radiotherapy on freedom
from seizures and survival time in dogs with brain tumors. We also
investigated whether the clinical presentation of seizures, magnetic
resonance imaging (MRI) characteristics of the lesions and drug dos-
age (AED and corticosteroids) would have confounded this outcome.
2 | METHODS
2.1 | Dogs
Medical records of dogs that presented between 2004 and 2011 with
seizures in association with neoplastic intracranial masses were
retrieved from 3 veterinary referral centers. The Queen's Veterinary
School Hospital (University of Cambridge, United Kingdom [UK]) and
the School of Veterinary Medicine (University of Glasgow, UK) pro-
vided the study population. Control data were acquired from a group
of dogs treated medically for brain tumors in a previously published
study from the Virginia Maryland College of Veterinary Medicine
(United States of America).2
Study and control dogs were included if they fulfilled the following
inclusion criteria: (a) clinical features of seizures and (b) MRI features of a
brain tumor. All dogs underwent MRI of the brain and only dogs in which
both a board-certified radiologist and neurologist had described a brain
tumor as the most likely differential diagnosis were included. The pre-
sumed diagnosis of brain tumor on MRI was based on lesion topography
(ie, number of lesions, shape of the lesion, and presence of mass effect,
dural tail [thickening of the dura adjacent to intracranial pathology on
contrast enhanced T1-W images] or contrast enhancement).6 Histopath-
ological data were analyzed when available. Dogs were excluded if they
underwent additional chemotherapy or brain surgery. The minimum
follow-up period for both groups was 12 months or until death or eutha-
nasia before reaching the end of the 12-month follow-up period.
2.2 | Radiotherapy and medical group
Dogs that received whole brain radiotherapy and medical treatment
formed the radiotherapy group and dogs that received medical
treatment alone formed the medical group. The radiotherapy
course (using 6 MV X-rays or 6-15 MeV electrons) was variable,
depending on institution, from 5 doses once weekly (1 × 5 Gy,
followed by 4 × 8.25 Gy—total dose of 38 Gy) for 15 dogs, 12 frac-
tions of 4 Gy each (total dose of 48 Gy) for 2 dogs or 15 fractions
of 3 Gy each (total dose of 45 Gy) for 1 dog (Supplementary
Data S1).
Medical treatment consisted of the use of AED (phenobarbital or
levetiracetam) and corticosteroids (prednisolone; Table 1).
2.3 | Retrieved data
Pretreatment data included age, sex, breed, and time between diagno-
sis and start of radiotherapy. In addition, onset of seizure activity, sei-
zure frequency (divided into: [1] 1 seizure episode, [2] ≥1 seizure
episode per month and < 1 per week, [3] ≥1 per week and < 1 per
day, [4] and > 1 per day), seizure type (focal [based on history, owner's
description and video when available] or generalized); presence of
cluster seizures (≥2 seizure episodes within 24 hours) or status
epilepticus (continued seizure activity >5 minutes or multiple seizures
for >30 minutes with impaired consciousness between seizures); pres-
ence of other neurological signs; and, dosage of AED, corticosteroids
or both given before radiotherapy. A seizure episode was defined as a
single seizure or a cluster of seizures.
Magnetic resonance imaging studies included a minimum of
T1-W (pre- and post-contrast) and T2-W sequences in transverse and
at least either sagittal or dorsal planes. Fluid-attenuated inversion
recovery (FLAIR) and gradient echo (GRE) sequences also were
included in most studies. The MRI characteristics of each suspected
tumor were assessed according to the following criteria: (a) whether
the neoplasia was intra-axial or extra-axial, (b) lesion localization (fron-
tal, temporal/piriform, parietal, occipital, olfactory, or other),
(c) presence or absence of perilesional extension into a different lobe,
(d) presence of edema or contrast enhancement (both subjectively
classified as none, mild, moderate, or severe), (e) presence or absence
of cystic structures, and (f) presence or absence of brain herniation or
dilatation of the ventricular system. The height of the lesion divided
by the height of the brain at its highest point (measured perpendicular
to the base plane of the skull) was calculated to determine a relative
ratio of the tumor to brain size. Any mass effect was calculated as the
largest deviation from midline in transverse sections. All measure-
ments on MRI were made using a computer software program
(Visbion) by one of 2 of the authors (SM and JHR) on T1-W post-
contrast images or T2-W images, if no contrast uptake was observed.
A tentative diagnosis of brain tumor type was made based on the MRI
findings. Definitive diagnosis by histopathological analysis was
recorded, if available.
After radiotherapy, the owners were contacted at the end of 2012
and, according a standard questionnaire, asked whether the animal's
seizures were controlled (defined as <1 seizure per month) before treat-
ment and to grade the animal's seizure frequency at 3, 6, and
12 months after treatment as part of clinical follow-up. The owners
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TABLE 1 Comparison of the baseline characteristics of the study population between both groups (radiotherapy and medical)
Variable
Radiotherapy
group (n = 18)
Medical
group (n = 14)
Statistics (P value) and statistical
test used
Sex (male/female) 12 (67%)/6(33%) 7 (50%)/7(50%) 0.4727 (Fisher's exact test)
Age (years) at presentation 8.3 ± 3.25 8.9 ± 4 0.4832 (t test)
Breed (brachycephalic/other) 4 (29%)/10(71%) 8 (44%/10(56%) 0.4709 (Fisher's exact test)
Seizure type
Generalized/Focal 18 (100%)/0(0%) 8 (57%)/6(43%) 0.0033 (Fisher's exact test)
Seizure presentation
Cluster seizures 22% (4/18) 72% (10/14) 0.011 (Fisher's exact test)
Status epilepticus 0% (0/18) 14% (2/14) 0.1835 (Fisher's exact test)
None of the above 78% (14/18) 14% (2/14) 0.0010 (Fisher's exact test)
Seizure frequency prior to therapy
1 seizure or cluster seizures
before treatment
33% (6/18) 29% (4/14) 1 (Fisher's exact test)
> or = 1/month during last
month before treatment
28% (5/18) 50% (7/14) 0.2769 (Fisher's exact test)
< or = 1/week during last
month before treatment
28% (5/18) 21%) (3/14) 1 (Fisher's exact test)
> or = 1/week during last
month before treatment
11% (2/18) 0% (0/14) 0.4919 (Fisher's exact test)
Tumor localization
Intraaxial/extra-axial 15 (83%)/3(17%) 6 (43%)/8(57%) 0.0265 (Fisher's exact test)
Lobe localization
Frontal 28% (5/18) 29% (4/14) 1 (Fisher's exact test)
Temporal/Piriform 39% (7/18) 14% (2/14) 0.2349 (Fisher's exact test)
Parietal 0% (0/18) 14% (2/14) 0.1835 (Fisher's exact test)
Occipital 11% (2/18) 14% (2/14) 1 (Fisher's exact test)
Olfactory 17% (3/18) 22% (3/14) 1 (Fisher's exact test)
Other 5% (1/18) 7% (1/14) 1 (Fisher's exact test)
Presence of perilesional
extension into another lobe
50% (9/18) 50% (7/14) 1 (Fisher's exact test)
Edema 0.054 (Mann–Whitney U test)
Mild 28% (5/18) 29% (4/14)
Moderate 28% (5/18) 36% (5/14)
Significant 44% (8/18) 14% (2/14)
None 0% (0/18) 21% (3/14)
Contrast enhancement 0.1679 (Mann–Whitney U test)
Mild 44% (8/18) 7% (1/14)
Moderate 11% (2/18) 36% (5/14)
Significant 28% (5/18) 43% (6/14)
None 17% (3/18) 14% (2/14)
Presence of cystic structures 67% (12/18) 43% (6/14) 0.2831 (Fisher's exact test)
Presence of brain herniation 11% (2/18) 36% (5/14) 0.1948 (Fisher's exact test)
Dilation of the ventricular
system
11% (2/18) 36% (5/14) 0.1948 (Fisher's exact test)
Tumor type
Glioma 78% (14/18) (based on
MRI appearance)
36% (5/14)
(confirmed)
0.0293 (Fisher's exact test)
(Continues)
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were not made aware of the purpose of the study. When available,
additional records about seizure activity of the patient before and after
initiation of treatment were reviewed. If the animal had been eutha-
nized, the owner was asked whether euthanasia was related to seizure
activity. The time when the animal was euthanized was recorded. For
each dog, seizure freedom was calculated, defined as the duration of
time that the dog remained seizure-free either since the start of radio-
therapy for the radiotherapy group or since the start of the drug treat-
ment for the medical group. Corticosteroid and AED dosages during the
course of medical treatment and radiotherapy also were recorded
(Table 1).
To identify errant variables (those nonrelated to treatment) that
might predispose patients to achieve seizure freedom, data from both
groups were compared, including patient signalment, clinical presenta-
tion (seizure characteristics), drug choice and dosage and MRI findings
(Table 2). Baseline characteristics of the 2 groups also were compared
(Table 1).
2.4 | Statistical analysis
The radiotherapy and medical treatment groups were compared
for seizure freedom and survival time, using a Kaplan-Meier Sur-
vival analysis. The level of significance was set at .05. Patients
were censored if lost for follow-up after 12 months, or if they died
of unrelated causes (the latter for assessment of the seizure
freedom).
Student t test, Mann-Whitney U test, and Fischer exact test were
used to compare baseline characteristics of both groups. The
Bonferroni correction was applied to correct for multiple comparisons,
with statistical significance established at .002.
A Cox's proportional hazard analysis was used to evaluate
whether the treatment effect on duration of seizure freedom could
have been confounded by group covariates, such as signalment, clini-
cal presentation, MRI characteristics, or AED dosage. The level of sig-
nificance was set at .05.
3 | RESULTS
3.1 | Population characteristics
Thirty-two dogs met the inclusion criteria: 18 dogs in the radiotherapy
group, and 14 dogs in the medical group. No differences in baseline
characteristics were observed between groups, except for seizure
TABLE 1 (Continued)
Variable
Radiotherapy
group (n = 18)
Medical
group (n = 14)
Statistics (P value) and statistical
test used
Meningioma 17% (3/18) (based on
MRI appearance)
50% (7/14)
(confirmed)
0.0623 (Fisher's exact test)
Other 5% (1/18) (based on
MRI appearance)
14% (2/14)
(confirmed)
0.5681 (Fisher's exact test)
Mass-effect 3.1 mm (median = 2.65,
IQR = 3.68)
2.5 mm (median = 2,
IQR = 4.25)
0.5360 (Mann-Whitney U test)
Brain:lesion size ratio 0.31 (median = 0.32,
IQR =0.118)
0.31 (median = 0.31,
IQR =0.155)
0.8958 (Mann-Whitney U test)
Medical treatment
Phenobarbitone 94% (17/18) median
max dose of
6.6 mg/kg/day
100% (14/14) median
max dose of
6.45 mg/kg/day
1 (Fisher's exact test)
Other AED 6% (1/18) 0% (0/14%) 1 (Fisher's exact test)
Corticosteroids (prednisolone) 94% (17/18) mean max
dose of 0.84 mg/kg/
day
79% (11/14) mean
max dose of
0.87 mg/kg/day
0.2951 (Fisher's exact test)
Note: t test, Mann-Whitney U test, and Fisher's exact test were used depending on the variable's characteristics. Due to multiple comparisons the
Bonferroni correction was applied, with statistical significance being established at P < .002.
TABLE 2 Cox proportional hazard analysis on selected variables,
evaluating association with seizure freedom
Variable
Statistics (P value)—Cox's
proportional hazard analysis
for association of parameter
with seizure freedom
Group .001
Seizure type .14
Seizure presentation .43
Seizure frequency prior
to treatment
.73
Brain:seizure size ratio .59
Edema .49
Tumor localization .80
Mass effect .49
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presentation, with single seizure episodes (P = .001) being overrepre-
sented in the radiotherapy group (Table 1). However, Cox hazard pro-
portional analysis (see later) did not identify any variables cofounding
the outcome (seizure freedom).
3.2 | Comparison of seizure freedom and survival
time between radiotherapy and medical groups
A statistically significant difference in freedom from seizures
(P < .001) was found between the 2 groups, with the radiotherapy
group showing markedly longer periods of seizure freedom. The
radiotherapy group had a mean seizure-free time of 24 months (95%
CI, 14.3-33.8) versus 1.7 months in the control group (95% CI,
0.5-2.9; Figure 1). Survival time also was significantly longer in the
radiotherapy group (P < .001), with a mean of 34.6 months (95% CI,
25.2-44.1) versus 6.2 months (95% CI, 2.6-9.7) in the control group
(Figure 2).
Nearly half (44.4%; 8/18) of the dogs included in the radiotherapy
group still were seizure-free by the end of the study, versus none
(0/14) of the medical group (Table 3).
In the radiotherapy group 5/18 dogs (27%) were euthanized
because of causes other than seizures. One dog was euthanized
because of anemia, another dog because of lymphoma (unrelated to the
central nervous system) and 3 dogs because of development of other
neurological signs. The surviving dogs with recurrence of seizures had
F IGURE 1 Kaplan–Meier
event-free survival curves,
comparing the cumulative
percentages of dogs in the
2 groups who were free of
seizures. Dogs of the
radiotherapy group (red)
remained free of seizures dogs for
longer as compared to dogs of
the medical group (blue),
following the start of therapy.
Note that time 0 is defined as the
start of radiotherapy for the
radiotherapy group or the start of
the drug therapy for the medical
group
F IGURE 2 Kaplan–Meier
survival curves, comparing the
cumulative percentages of dogs in
the 2 groups. Dogs of the
radiotherapy group (red) had a
longer survival time as compared
to dogs of the medical group
(blue), following the start of
therapy. Note that time 0 is
defined as the start of
radiotherapy for the radiotherapy
group or the start of the drug
therapy for the medical group
MONFORTE MONTEIRO ET AL. 5
less severe seizure forms (changing from generalized to focal) or only
1 or 2 episodes after the course of radiotherapy (Figure 2).
In the medical group, all the dogs had died or been euthanized by
the end of the study, 71% (10/14) because of seizure activity and
29% (4/14) because of the development of other neurological signs.
3.3 | Confounding variables
A Cox proportional analysis was used to explore whether signalment,
clinical presentation, MRI characteristics or drug dosage could have
confounded the time of seizure freedom after radiotherapy. None of
the explored characteristics was found to be associated in a statistically
significant manner with time of seizure freedom after intervention
(Table 2). Only group (radiotherapy versus medical) was significantly dif-
ferent (P = .001).
4 | DISCUSSION
To our knowledge, this study is the first to investigate the potential of
radiotherapy to prolong seizure freedom in dogs with brain tumors, and
suggests that radiotherapy decreases seizure frequency in dogs. Similar
findings have been observed in humans patients with brain tumors
treated with radiotherapy.5 This information is crucial for the owner's
decision making when choosing whether to pursue further treatment or
not, because often recurrence of seizures is a common reason for eutha-
nasia7 in these patients. Interestingly, in our study 70% of the dogs in the
medical group were euthanized because of seizure activity rather than
other neurological impairment, which could indicate the importance of
seizure freedom on the perceived quality of life of the dog for the
owners. Similar findings have been described previously.7
The significant difference between seizure-free duration in the
radiotherapy group as compared to the control group allows radiation
therapy to be presented to owners as a potential aid in seizure control
in dogs with brain tumors. However, because ours was a retrospective
study, prospective studies are warranted to confirm this observation.
The reason for the increased duration of seizure freedom after
radiotherapy observed in our study remains unclear. In a study of
humans with gliomas5 a significant difference in seizure freedom was
achieved at 12 months in 32%-38% of patients. Only the duration of
seizures before radiotherapy influenced outcome: Patients with a sei-
zure history of >1 year before radiotherapy had a worse outcome.5
No significant correlation was found between patients with seizure
reduction and reduction of tumor size after radiotherapy.5 In our
study, tumor size after radiotherapy was unknown, because the
owners declined repeated MRI. Based on extrapolation from studies
in humans, we speculate that the role of radiotherapy in seizure con-
trol is not related directly to tumor size, and it is postulated that
another mechanism likely plays a role, particularly in those patients
with no tumor size reduction.5
Epileptogenesis in patients with brain tumors still is not well
understood. Tumors in the frontal, temporal, and parietal lobes and in
the olfactory bulb have been associated with an increased incidence
of seizures.1 The epileptogenic zone often is not restricted to the
tumor area. Perilesional edema also is implicated in the mechanism of
epileptogenesis.,1,8 In fact, in approximately one-third of the human
patients, the epileptogenic zone is not within the tumor itself, but in
the surrounding brain tissue.9 Seizures in humans generally are associ-
ated with low-grade tumors, suggesting that slow rate growth might
allow time for development of functional (rather than structural)
changes to occur in the tumor cells and surrounding tissue.10
The use of radiation therapy, although aiming to destroy the neoplas-
tic cells, also damages surrounding brain tissue. Because the peritumoral
area is the most likely site for the seizure focus, the effect of radiotherapy
on the myelin and thus electrical conduction, and also on altered neurons,
conceivably could eliminate the functional deficits.11 This effect could
lead to eliminating the source of the hyperexcitability, and therefore the
seizures, without a marked decrease in lesion size. Further studies would
be necessary to validate this hypothesis.
Our study had a number of limitations. Only the control group had
histologically confirmed tumors. None of the dogs in the radiotherapy
group that died had necropsy performed, thus the exact histological
origin of the presumed tumor on MRI remains unknown. It is known
that MRI has a sensitivity of approximately 90% and specificity of
approximately 87% for correct identification of brain neoplasia.10 It
also has been shown, however, that cerebrovascular incidents can be
mistaken for brain tumors.6 Using diffusion-weighted sequences would
be an appropriate method to differentiate between tumor and cerebro-
vascular incident. In veterinary practice, most animals with brain
tumors are irradiated based on MRI findings, and most owners are not
willing to have a brain biopsy performed on their animal. The MRI char-
acteristics of the tumors were not significantly different between
groups. The time and choice of euthanasia also might contribute bias,
because owners electing radiotherapy might be more motivated and
euthanize their dogs later when compared to owners who have chosen
medical treatment alone. The decision for euthanasia in dogs with
symptomatic epilepsy is largely dependent on the owner's personal
view on the animal's quality of life.7 As a retrospective study, some of
the radiation therapy protocols differ from most current ones.12 Our
study included a control group from a different time period and loca-
tion (USA) than the radiotherapy group, which increases the risk of
confounders. The demographics of the 2 populations were similar with
TABLE 3 Comparison of seizure freedom at different times
between the radiotherapy and medical groups
Seizure freedom
Radiotherapy
group
(n = 18)
Medical
group
(n = 14)
Seizure free time < 3 mo 11% (n = 2) 8 (57%)
Seizure free time 3–6 mo 1 (6%) 4 (29%)
Seizure free time 6–9 mo 2 (11%) 2 (14%)
Seizure free time 9-12 mo 2 (11%) 0 (0%)
Seizure free time > 12 mo 11 (61%) 0 (0%)
Seizure free by end of study 8 (44.4%) 0 (0%)
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the exception of seizure presentation, with dogs in the radiotherapy
group being presented mainly with single seizures. None of the vari-
ables recorded, however, had a significant association with freedom
from seizures, with the exception of treatment modality. Other
unrecorded characteristics related to the geographic differences
between populations, such as diet and environment, could have an
influence. The time between presenting seizure activity and the collec-
tion of information from the owners may have led to some recall bias.
It would have been useful to evaluate the efficacy of radiation therapy
in decreasing seizure frequency by comparing seizure frequency before
and after treatment between the 2 groups. Doing so was not possible
in our study because intervention (both medical or radiotherapy) was
started soon after the onset of seizures and diagnosis. A prospective
study could further explore this question.
In conclusion, in our study a longer period of seizure freedom was
observed in dogs with brain tumors after radiotherapy compared with
those that received medical treatment alone. These findings encour-
age performance of a prospective multicenter study to confirm our
results. Such information might help owners in their decision whether
to pursue radiotherapy as a treatment option for animals with
suspected brain tumors. Further prospective case-controlled, blinded,
randomized studies are needed in humans and dogs to investigate
underlying pathophysiological mechanisms, because tumor size and
shrinkage and severity of edema do not seem to be the only reasons
for the decrease in seizure frequency.
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